Informed Prostate Cancer Patient Support

Standard v Patient Centered Reports New Study Shows Patient-Friendly Pathology Reports Improve Understanding of Prostate Cancer Diagnosis A recent study published in JAMA has revealed that a new type of pathology report, called the Patient-Centered Pathology Report (PCPR), significantly improves patients’ ability to understand their prostate cancer diagnosis compared to traditional reports. The findings could have a major impact on how men process and respond to their biopsy results, helping them make more informed decisions about their care. Understanding the PCPR Difference Pathology reports are a crucial part of a prostate cancer diagnosis, but they are often filled with complex medical terminology that can be difficult for patients to interpret. The study compared three types of reports: a standard university format, a Veterans Affairs (VA) format, and the PCPR. Researchers found that 93% of patients who received a PCPR correctly identified their diagnosis as prostate cancer, comp...

64 CuCl 2 PET/CT in Prostate Cancer Relapse A 70-y-old man with Gleason 4 + 3 PCa treated with radical prostatectomy, with rising PSA level (1.34) and PSA doubling time of 5.3 mo. (A) 64 CuCl 2 PET/CT images reveals focal uptake (dotted arrow) in residual right seminal vesicle. (B) 18 F-choline PET/CT is negative. (C) T2-weighted axial image mpMRI shows hypointense area in right seminal vesicle remnants. (D) Apparent-diffusion-coefficient map derived from diffusion-weighted imaging sequence shows focal area of signal restriction in correspondence to remnants of right seminal vesicle. New Copper-Based PET Scan Shows Promise for Detecting Prostate Cancer Recurrence Novel imaging technique may provide better detection of returning prostate cancer, especially when PSA levels are low A new clinical trial (EudraCT Number: 2017-004332-11) investigating an innovative imaging technique could bring hope to men experiencing biochemical recurrence after prostate cancer treatment. The st...

Study Reinforces CVD, Other Non-Cancer Causes of Death in Men With Prostate Cancer | MedPage Today — Prostate cancer accounted for only 15% of deaths during 11 years of follow-up medpagetoday.com Senior Editor, MedPage Today Oncology/Hematology > Prostate Cancer by Charles Bankhead , February 26, 2025 Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in all-cause and cardiovascular disease-related mortality. Since 85% ...

Genetic Testing for Cancer: A Powerful Tool for Prevention and Treatment Genetic testing for cancer is increasingly becoming an essential component of cancer prevention and treatment strategies, yet remains significantly underutilized. Only about 6.8% of cancer patients undergo genetic testing despite recommendations from medical experts, according to a study reported by the National Cancer Institute in 2023. What is genetic testing for cancer? Genetic testing looks for specific inherited changes or mutations in a person's genes that may increase the risk of developing certain types of cancer. While most cancers are not inherited, about 5-10% of all cancers are thought to be caused by harmful genetic changes passed down from parents. "Genetic testing is now absolutely essential to cancer treatment and prevention," said Allison Kurian, a professor at Stanford Medicine and director of the Stanford Women's Clinical Cancer Genetics Program. "It's underused, a...